AsedaSciences, Biobide link aquatic toxicity testing to 3RnD platform

AsedaSciences and Biobide have struck a strategic sales and marketing agreement to bring aquatic toxicity screening services into the 3RnD platform. The move gives chemical developers a single place to order studies, manage toxicology data and compare results across screening methods.

Why it matters: - The agreement expands access to New Approach Methodologies, or NAMs, for toxicity risk assessment in chemical development. - The combined offering is designed to reduce the time and complexity of ordering studies, managing results and interpreting toxicity data. - Researchers and product developers can use one platform to compare findings across multiple screening methods and benchmark compounds against known toxicity profiles.

What happened: - AsedaSciences and Biobide announced a strategic sales and marketing agreement on July 1, 2026. - The partnership integrates Biobide’s aquatic toxicity screening services into the AsedaSciences 3RnD platform. - The collaboration gives users direct access to aquatic toxicity studies through 3RnD. - Brad Calvin, CEO of AsedaSciences, said the integration makes high-quality NAM screening services more accessible and actionable. - Andoni Cruz, managing director of Biobide, said the collaboration connects aquatic toxicity screening with a digital platform built for modern toxicology workflows.

The details: - The 3RnD platform will serve as a centralized place to order NAMs for toxicity risk assessment. - The platform will also manage study data and support earlier insight into compound safety profiles. - Users will be able to move from study ordering to data delivery and analysis in a single workflow. - The integrated system adds aquatic toxicity testing to 3RnD’s NAM-based screening lineup. - Researchers can link and review data for a given compound in one secure interface. - The platform will consolidate and visualize data from multiple screening methods. - AsedaSciences and Biobide will expand a comparative library of compounds screened across their methodologies. - The reference database will help users interpret results by comparing them with compounds that have established toxicity profiles. - Customer data will be stored in a private, secure environment. - Users will still be able to benchmark against relevant library compounds generated through the same screening systems. - For AsedaSciences, the agreement rounds out aquatic toxicity capabilities within 3RnD. - For Biobide, the partnership adds access to an e-commerce and data delivery platform that simplifies the customer experience. - Through 3RnD, customers can order aquatic toxicity studies in a streamlined, hands-off process and receive results in one place. - Biobide is part of Biat Group and is listed on BME under the ticker BST. - Biobide provides aquatic toxicity screening and GLP regulatory services across multiple industries. - AsedaSciences develops the 3RnD platform as an integrated digital ecosystem for NAM access, toxicology data centralization and data visualization.

Between the lines: - The partnership points to a broader push to connect lab testing with digital data tools instead of treating them as separate steps. - The emphasis on comparative libraries suggests customers want not just raw test results but context for decision-making. - The agreement also signals that NAM adoption is moving deeper into pharmaceutical, consumer product, agricultural and industrial chemical workflows.

What's next: - AsedaSciences and Biobide will work together to expand the compound reference library. - More customers are likely to use 3RnD as a single entry point for ordering, data review and comparative toxicology analysis. - The companies expect the integrated workflow to support faster and more informed safety assessment and product development decisions.